{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:54:23Z","timestamp":1793498063512,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.annonc.2020.08.2099","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:00:19Z","timestamp":1598500819000},"page":"1476-1490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":427,"title":["Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"31","author":[{"given":"M.","family":"Fassnacht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Assie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Eisenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"de la Fouchardiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Krijger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Porpiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Terzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.08.2099_bib1","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"key":"10.1016\/j.annonc.2020.08.2099_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","article-title":"Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005","volume":"3","author":"Pacak","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib6","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1210\/jc.2004-1398","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/er.2002-0031","article-title":"The clinically inapparent adrenal mass: update in diagnosis and management","volume":"25","author":"Mansmann","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.annonc.2020.08.2099_bib9","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib10","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib12","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib13","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1373\/clinchem.2017.277624","article-title":"A\u00a013-steroid serum panel based on LC-MS\/MS: use in detection of adrenocortical carcinoma","volume":"63","author":"Taylor","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.annonc.2020.08.2099_bib14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1373\/clinchem.2017.271106","article-title":"High-resolution, accurate-mass (HRAM) mass spectrometry urine steroid profiling in the diagnosis of adrenal disorders","volume":"63","author":"Hines","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.annonc.2020.08.2099_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/EJE-18-0782","article-title":"Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma","volume":"180","author":"Schweitzer","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12672-015-0224-3","article-title":"Diagnostic value of urinary steroid profiling in the evaluation of adrenal tumors","volume":"6","author":"Kerkhofs","year":"2015","journal-title":"Horm Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib17","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1530\/EJE-16-0461","article-title":"Management of endocrine disease: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis","volume":"175","author":"Dinnes","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000478-198403000-00001","article-title":"Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors","volume":"8","author":"Weiss","year":"1984","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib22","doi-asserted-by":"crossref","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2020.08.2099_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.annonc.2020.08.2099_bib24","series-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2017"},{"key":"10.1016\/j.annonc.2020.08.2099_bib25","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib26","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djt201","article-title":"Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction","volume":"105","author":"Jochmanova","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.08.2099_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2020.08.2099_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib29","doi-asserted-by":"crossref","first-page":"T201","DOI":"10.1530\/ERC-18-0085","article-title":"65 years of the double helix: genetics informs precision practice in the diagnosis and management of pheochromocytoma","volume":"25","author":"Neumann","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev"},{"key":"10.1016\/j.annonc.2020.08.2099_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"Toledo","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1055\/a-0672-1266","article-title":"An update on the histology of pheochromocytomas: how does it relate to genetics?","volume":"51","author":"Oudijk","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.annonc.2020.08.2099_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib34","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-14-0756","article-title":"Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma","volume":"172","author":"Sue","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib37","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Libe","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib38","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1210\/jc.2010-0803","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"Fassnacht","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/EJE-18-0450","article-title":"Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis","volume":"179","author":"Vanbrabant","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib40","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/archsurg.2009.191","article-title":"Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty?","volume":"144","author":"Park","year":"2009","journal-title":"Arch Surg"},{"key":"10.1016\/j.annonc.2020.08.2099_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/EJE-13-0142","article-title":"Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data","volume":"169","author":"Kerkhofs","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00423-011-0866-8","article-title":"Adrenocortical carcinoma: effect of hospital volume on patient outcome","volume":"397","author":"Lombardi","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.annonc.2020.08.2099_bib43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.annonc.2020.08.2099_bib44","first-page":"U885","article-title":"Deficits in the management of patients with adrenocortical carcinoma in Germany","volume":"107","author":"Johanssen","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.annonc.2020.08.2099_bib45","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/SLA.0b013e3182367ac3","article-title":"Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma","volume":"255","author":"Reibetanz","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2020.08.2099_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1245\/s10434-018-6999-z","article-title":"Patterns of lymph node recurrence in adrenocortical carcinoma: possible implications for primary surgical treatment","volume":"26","author":"Reibetanz","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40618-015-0422-4","article-title":"Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?","volume":"39","author":"Porpiglia","year":"2016","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.annonc.2020.08.2099_bib49","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.annonc.2020.08.2099_bib51","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2099_bib52","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib53","doi-asserted-by":"crossref","first-page":"9362108","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.annonc.2020.08.2099_bib54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib56","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00002018-200730110-00004","article-title":"Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management","volume":"30","author":"Eisenhofer","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.annonc.2020.08.2099_bib57","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1530\/EJE-07-0723","article-title":"Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma","volume":"158","author":"Hermsen","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12672-011-0094-2","article-title":"Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?","volume":"2","author":"Baudin","year":"2011","journal-title":"Horm Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ecl.2015.03.001","article-title":"Adrenocortical carcinoma","volume":"44","author":"Baudin","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.annonc.2020.08.2099_bib60","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.08.2099_bib61","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","article-title":"Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma \u2013 a Southwest Oncology Group study","volume":"88","author":"Williamson","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.1993.11.1.161","article-title":"Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study","volume":"11","author":"Bukowski","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/a-0715-1946","article-title":"Advanced adrenocortical carcinoma \u2013 what to do when first-line therapy fails?","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib64","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib65","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib67","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","article-title":"Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy","volume":"38","author":"Bednarski","year":"2014","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.annonc.2020.08.2099_bib68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12020-017-1428-9","article-title":"Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma","volume":"61","author":"Claps","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.annonc.2020.08.2099_bib69","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jc.2012-2559","article-title":"The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib71","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.annonc.2020.08.2099_bib72","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib73","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib77","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2020.08.2099_bib79","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib80","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","article-title":"Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma","volume":"59","author":"Gravel","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.annonc.2020.08.2099_bib81","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity I-131 MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.annonc.2020.08.2099_bib83","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA-conjugated somatostatin receptor targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"60","author":"Han","year":"2019","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.annonc.2020.08.2099_bib84","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib85","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.annonc.2020.08.2099_bib86","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib87","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2020.08.2099_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/1179554918763367","article-title":"Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature","volume":"12","author":"Tena","year":"2018","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.annonc.2020.08.2099_bib90","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2020.08.2099_bib91","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.annonc.2020.08.2099_bib92","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2022.12.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420421076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420421076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T20:59:32Z","timestamp":1697144372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420421076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0923753420421076"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}